Clinical
RSSArticles
-
Home BP Monitoring vs Ambulatory BP Monitoring
Clinicians should routinely use ambulatory blood pressure monitoring or home blood pressure monitoring prior to initiating treatment for hypertension.
-
FDA Actions
In this section: boxed warning to all immediate-release opioids; eased restrictions on mifepristone used with misoprostol used for medical abortions; reslizumab for the maintenance treatment of severe asthma; and ixekizumab for the treatment of adults with moderate-to-severe plaque psoriasis.
-
New Guidelines for Dual Antiplatelet Therapy
The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event.
-
More Evidence Supports Timing Hypothesis for Hormone Therapy
More evidence that supports the timing hypothesis (or the critical window-of-opportunity hypothesis) for hormone therapy to slow atherosclerosis progression.
-
Federal Agencies, States Move Swiftly to Combat Opioid Overdose Epidemic
CDC issues new pain management guidelines; White House, states bring own ideas to the table.
-
Chest Pain and Giant T Wave Inversion
Chest pain (rather than shortness of breath) and ST elevation (rather than T wave inversion) in leads V1 and V2 make massive pulmonary embolism unlikely.
-
Clinical Briefs
In this section: the insulin misadministration problem; comparing smoking cessation pharmacotherapies; more support for ambulatory BP monitoring.
-
Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate
Tenofovir alafenamide has replaced the tenofovir disoproxil fumarate component of two commonly used drug combinations for HIV-1 infection.
-
ICH May Clinically Mimic TIA
In a large retrospective review of 2137 patients with intracerebral hemorrhage, 34 presented with transient symptoms that could have been misclassified as “transient ischemic attack” if brain imaging had not been performed.
-
Selecting Patients for Statin Primary Prevention
The new vascular disease risk calculator discriminates who will experience a vascular event in the near future better than using a trial entry criteria approach or a hybrid approach.